Nov 3, 2021
Francois Michelon is the CEO of ENDRA Life Sciences and describes the thermoacoustic enhanced ultrasound -TAEUS-technology ENDRA is developing to provide a safe and cost-effective way to measure the fat in the liver and diagnose non-alcoholic fatty liver disease (NAFLD). NAFLD is overtaking hepatitis as the world's leading root cause of the need for liver transplants. Current diagnostic options are using expensive MRI machines or performing a liver biopsy.
Francois says, "There are no blood tests that currently we're aware of that can measure fat in your liver. It's not like cholesterol that floats around in your bloodstream. You have to measure it directly, and it doesn't even deposit uniformly in your liver."
"ENDRA's technology uses a combination of radiofrequency pulses, which are akin to an MRI going in. Those radiofrequency pulses get absorbed differently into tissues. And we've been able to decode the sonic sound waves that come back out of tissues from that absorption of radiofrequency."
"As a result, we can do things that are very different from ultrasound, including measuring fat in the liver, along with other things like showing tissue temperature change to guide thermal ablative surgeries and other things that we have in our roadmap."
@ENDRALifeSci #NAFLD #NASH #LiverDisease #Ultrasound #TAEUS